Development and Validation of a Nomogram to Predict the Recurrence of HCC Patients Undergoing CECT After Ablation

被引:2
作者
Qiao, Wenying [1 ,2 ,3 ]
Fan, Zibo [2 ]
Wang, Qi [2 ]
Jin, Ronghua [2 ,3 ,5 ]
Hu, Caixia [1 ,4 ]
机构
[1] Capital Med Univ, Beijing Youan Hosp, Intervent Therapy Ctr Oncol, Beijing, Peoples R China
[2] Capital Med Univ, Beijing Ditan Hosp, Beijing, Peoples R China
[3] Changping Lab, Beijing, Peoples R China
[4] Capital Med Univ, Beijing Youan Hosp, Intervent Therapy Ctr Oncol, 8 Xitoutiao,Youanmenwai St, Beijing, Peoples R China
[5] Capital Med Univ, Beijing Ditan Hosp, 8 Jingshun East St, Beijing, Peoples R China
关键词
hepatocellular carcinoma; transcatheter arterial chemoembolization; contrast-enhanced computed tomography; recurrence-free survival; risk factors; HEPATOCELLULAR-CARCINOMA; RADIOFREQUENCY ABLATION; RISK; ULTRASOUND; CONSENSUS; RATIO;
D O I
10.2147/JHC.S441540
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: We first aimed to compare the prognostic difference between the application of Contrast-enhanced computed tomography (CECT) and Non-enhanced computed tomography (NECT) in hepatocellular carcinoma(HCC) patients with early-stage immediately after ablation. We secondly propose to explore the risk factors for recurrence in patients undergoing CECT, and then develop a nomogram.Patients and Methods: Clinical data were collected from 711 patients who received TACE combined with ablation from January 1, 2015, to December 31, 2022, at Beijing Youan Hospital. According to the imaging methods applied after ablation, patients were categorized into the CECT group and the NECT group and then were compared by Kaplan-Meier (KM) curves. Lasso regression is used to screen risk factors for recurrence and the nomogram was plotted. Finally, discrimination, calibration plot, and decision curve analysis (DCA) were used to measure the performance of the nomogram.Results: The KM curve indicates that recurrence-free survival (RFS) was longer in the CECT group than in the NECT group (HR =0.759, 95% CI 0.606-0.951, P=0.016). Six variables were selected to construct the nomogram. 1-, 3-, and 5-year area under the curves (AUCs) (0.867, 0.731, 0.773 and 0.896, 0.784, 0.773) of the training and validation cohorts proved the good predictive performance of the nomogram. Calibration curves and DCA curves suggested accuracy and net clinical benefit rates. The nomogram enabled to classify of patients into three groups according to the risk of recurrence: low risk, intermediate risk, and high risk. There was a statistically significant difference in RFS between the two groups in the training and validation cohorts (P<0.001).Conclusion: We demonstrated that HCC patients who underwent CECT evaluation after ablation had a better prognosis, making this evaluation method highly recommended for guiding clinical management.
引用
收藏
页码:65 / 79
页数:15
相关论文
共 36 条
[1]   Hepatic Radiofrequency Ablation-induced Stimulation of Distant Tumor Growth Is Suppressed by c-Met Inhibition [J].
Ahmed, Muneeb ;
Kumar, Gaurav ;
Moussa, Marwan ;
Wang, Yuanguo ;
Rozenblum, Nir ;
Galun, Eithan ;
Goldberg, S. Nahum .
RADIOLOGY, 2016, 279 (01) :103-117
[2]   Challenges in liver cancer and possible treatment approaches [J].
Anwanwan, David ;
Singh, Santosh Kumar ;
Singh, Shriti ;
Saikam, Varma ;
Singh, Rajesh .
BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER, 2020, 1873 (01)
[3]   Recent Advances in Local Thermal Ablation Therapy for Hepatocellular Carcinoma [J].
Deng, Min ;
Li, Shao-Hua ;
Guo, Rong-Ping .
AMERICAN SURGEON, 2023, 89 (05) :1966-1973
[4]   Prognostic significance of pretreatment albumin/globulin ratio in patients with hepatocellular carcinoma [J].
Deng, Yan ;
Pang, Qing ;
Miao, Run-Chen ;
Chen, Wei ;
Zhou, Yan-Yan ;
Bi, Jian-Bin ;
Liu, Su-Shun ;
Zhang, Jing-Yao ;
Qu, Kai ;
Liu, Chang .
ONCOTARGETS AND THERAPY, 2016, 9 :5317-5328
[5]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[6]   Risk factors and prevention of hepatocellular carcinoma in the era of precision medicine [J].
Fujiwara, Naoto ;
Friedman, Scott L. ;
Goossens, Nicolas ;
Hoshida, Yujin .
JOURNAL OF HEPATOLOGY, 2018, 68 (03) :526-549
[7]   Liver cirrhosis [J].
Gines, Pere ;
Krag, Aleksander ;
Abraldes, Juan G. ;
Sola, Elsa ;
Fabrellas, Nuria ;
Kamath, Patrick S. .
LANCET, 2021, 398 (10308) :1359-1376
[8]   Gamma-Glutamyl Transpeptidase: Redox Regulation and Drug Resistance [J].
Hanigan, Marie H. .
REDOX AND CANCER, PT A, 2014, 122 :103-141
[9]   AASLD guidelines for the treatment of hepatocellular carcinoma [J].
Heimbach, Julie K. ;
Kulik, Laura M. ;
Finn, Richard S. ;
Sirlin, Claude B. ;
Abecassis, Michael M. ;
Roberts, Lewis R. ;
Zhu, Andrew X. ;
Murad, M. Hassan ;
Marrero, Jorge A. .
HEPATOLOGY, 2018, 67 (01) :358-380
[10]   Surgery for Intermediate and Advanced Hepatocellular Carcinoma: A Consensus Report from the 5th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2014) [J].
Ho, Ming-Chih ;
Hasegawa, Kiyoshi ;
Chen, Xiao-Ping ;
Nagano, Hiroaki ;
Lee, Young-Joo ;
Chau, Gar-Yang ;
Zhou, Jian ;
Wang, Chih-Chi ;
Choi, Young Rok ;
Poon, Ronnie Tung-Ping ;
Kokudo, Norihiro .
LIVER CANCER, 2016, 5 (04) :245-256